#China #Hong Kong #Akeso #Ivonescimab #NSCLC

Introduction

In a pivotal breakthrough for oncology, ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by Akeso, Inc., has received major endorsements in the 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (NSCLC). The recognition acknowledges ivonescimab's effectiveness and positions it at the forefront of cancer therapy, potentially altering treatment paradigms for thousands of patients.

Background

Akeso, a biopharmaceutical firm known for its innovative approach, has made significant strides since its inception in 2012. The company is dedicated to the research and development of advanced therapeutics for cancer and other severe conditions. The introduction of ivonescimab marks a milestone in their journey, reflecting their commitment to delivering high-quality medical solutions to patients worldwide.

Key Recommendations in the CSCO Guidelines

The 2026 CSCO guidelines provide comprehensive recommendations regarding ivonescimab's use across various treatment settings, with updates based on robust clinical trial data that underline its efficacy. Notably, the following recommendations were highlighted:

1. Class I Recommendations

• - First-Line Treatment for PD-L1 Positive NSCLC: In the Phase III HARMONi-2 study, ivonescimab showcased superior progression-free survival compared to pembrolizumab in first-line settings for patients with PD-L1 TPS ≥1%. This led to its upgrade to a Class I recommendation, signifying it as a preferred choice for advanced NSCLC.
• - Advanced Driver Gene-Negative NSCLC: For patients with advanced driver gene-negative non-squamous and squamous NSCLC with PD-L1 TPS ≥1%, ivonescimab monotherapy is now recognized under Class I, further emphasizing its clinical value.

2. Class II Recommendations

• - Combination Therapy: The Phase III HARMONi-6 study demonstrated positive outcomes for ivonescimab plus chemotherapy against PD-1 inhibitors combined with chemotherapy in first-line squamous NSCLC. This protocol has received a Class II recommendation, and efforts for its regulatory approval are underway.

Clinical Impact and Future Directions

More than 70,000 patients have contributed to the growing body of evidence supporting ivonescimab's efficacy through various clinical trials and real-world applications. Oncologists across the globe are adopting this treatment, as it reflects a progressive step toward personalized cancer care that aligns with today’s therapeutic goals.

Next Generation Immunotherapy

The advancements brought forth by ivonescimab are indicative of a larger shift towards next-generation immunotherapy, which is an essential component of the evolving IO 2.0 landscape. Akeso's methodologies, including AI-powered research and various innovative platforms, ensure that the company is prepared for continued innovations aimed at uplifting patient care standards.

About Akeso

Akeso stands as a beacon of hope in the biopharmaceutical industry. With cutting-edge technologies and a strong commitment to drug development, the company is not only pushing boundaries but also shaping the future of cancer treatments. The implementation of integrated platforms for research and commercialization has allowed Akeso to streamline processes and develop remarkable assets that challenge conventional therapeutic options.

Conclusion

The 2026 CSCO guideline recommendations for ivonescimab come as a testament to Akeso's dedication and innovative spirit in the fight against NSCLC. As medical professionals embrace these guidelines, the future looks promising for many patients who have long awaited advancements in lung cancer therapy. The journey ahead will undoubtedly be shaped by the continued successes of ivonescimab and the ongoing commitment to groundbreaking oncology research.